BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lv H, Wu NC, Tsang OT, Yuan M, Perera RAPM, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH, Wang Y, Choi CYC, Lin Y, Ng WW, Zhao J, Poon LLM, Peiris JSM, Wilson IA, Mok CKP. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep 2020;31:107725. [PMID: 32426212 DOI: 10.1016/j.celrep.2020.107725] [Cited by in Crossref: 266] [Cited by in F6Publishing: 299] [Article Influence: 133.0] [Reference Citation Analysis]
Number Citing Articles
1 Rong G, Zheng Y, Chen Y, Zhang Y, Zhu P, Sawan M. COVID-19 Diagnostic Methods and Detection Techniques. Encyclopedia of Sensors and Biosensors 2023. [DOI: 10.1016/b978-0-12-822548-6.00080-7] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Jia L, Weng S, Wu J, Tian X, Zhang Y, Wang X, Wang J, Yan D, Wang W, Fang F, Zhu Z, Qiu C, Zhang W, Xu Y, Wan Y. Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. Gut Microbes 2022;14:2117503. [DOI: 10.1080/19490976.2022.2117503] [Reference Citation Analysis]
3 Liang H, Zheng P, Wang Q, Deng Y, Liang D, Yi H, Cheng Y, Zhao X, Ma J, Yang Y, Hu P, Zheng P, Zhang Y, Huang S, Lin X, Ke C, Niu X, Sun B, Chen L. Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection. Emerg Microbes Infect 2022;11:1500-7. [PMID: 35615992 DOI: 10.1080/22221751.2022.2076613] [Reference Citation Analysis]
4 Trombetta CM, Marchi S, Viviani S, Manenti A, Casa E, Dapporto F, Remarque EJ, Bollati V, Manini I, Lazzeri G, Montomoli E. A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019? Hum Vaccin Immunother 2022;18:2047582. [PMID: 35289714 DOI: 10.1080/21645515.2022.2047582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ang GY, Chan KG, Yean CY, Yu CY. Lateral Flow Immunoassays for SARS-CoV-2. Diagnostics 2022;12:2854. [DOI: 10.3390/diagnostics12112854] [Reference Citation Analysis]
6 Wang L, Zhao J, Schank M, Khanal S, Dang X, Cao D, Nguyen LN, Zhang Y, Wu XY, Adkins JL, Brueggeman J, Zhang J, Ning S, El Gazzar M, Moorman JP, Yao ZQ. Identification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patients. Molecular Immunology 2022. [DOI: 10.1016/j.molimm.2022.10.016] [Reference Citation Analysis]
7 Pacheco-olvera DL, Saint Remy-hernández S, García-valeriano MG, Rivera-hernández T, López-macías C. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. Archives of Medical Research 2022. [DOI: 10.1016/j.arcmed.2022.10.007] [Reference Citation Analysis]
8 Shehu IA, Musa MK, Datta A, Verma A. Application of Nanotechnology in COVID-19 Infection: Findings and Limitations. JNT 2022;3:203-232. [DOI: 10.3390/jnt3040014] [Reference Citation Analysis]
9 Alsalameh S, Alnajjar K, Makhzoum T, Al Eman N, Shakir I, Mir TA, Alkattan K, Chinnappan R, Yaqinuddin A. Advances in Biosensing Technologies for Diagnosis of COVID-19. Biosensors (Basel) 2022;12:898. [PMID: 36291035 DOI: 10.3390/bios12100898] [Reference Citation Analysis]
10 Lee B, Ko JH, Lee KH, Kim YC, Song YG, Park YS, Baek YJ, Ahn JY, Choi JY, Song KH, Kim ES, Bae S, Kim SH, Jeong HW, Kim SW, Kwon KT, Kim SH, Jeong H, Kim B, Kim SS, Choi WS, Peck KR, Kang ES. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain. Microbiol Spectr 2022;:e0266922. [PMID: 36250875 DOI: 10.1128/spectrum.02669-22] [Reference Citation Analysis]
11 Celikgil A, Massimi AB, Nakouzi A, Herrera NG, Morano NC, Lee JH, Yoon HA, Garforth SJ, Almo SC. SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients.. [DOI: 10.1101/2022.10.14.512324] [Reference Citation Analysis]
12 van Rijswijck DMH, Bondt A, Hoek M, van der Straten K, Caniels TG, Poniman M, Eggink D, Reusken C, de Bree GJ, Sanders RW, van Gils MJ, Heck AJR. Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern. Nat Commun 2022;13:6103. [PMID: 36243713 DOI: 10.1038/s41467-022-33899-1] [Reference Citation Analysis]
13 Soni I, Kumar P, Jayaprakash GK, Pandith A. A Short Review Comparing Carbon‐Based Electrochemical Platforms With Other Materials For Biosensing SARS‐Cov‐2. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202202465] [Reference Citation Analysis]
14 Vojdani A, Vojdani E, Melgar AL, Redd J. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front Immunol 2022;13:1003094. [DOI: 10.3389/fimmu.2022.1003094] [Reference Citation Analysis]
15 Wang S, Wu D, Xiong H, Wang J, Tang Z, Chen Z, Wang Y, Zhang Y, Ying D, Lin X, Liu C, Guo S, Tian W, Lin Y, Zhang X, Yuan Q, Yu H, Zhang T, Zheng Z, Xia N. Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. Front Immunol 2022;13:952650. [DOI: 10.3389/fimmu.2022.952650] [Reference Citation Analysis]
16 de Souza MO, Madan B, Teng I, Huang A, Liu L, Fahad AS, Lopez Acevedo SN, Pan X, Sastry M, Gutierrez-gonzalez M, Yin MT, Zhou T, Ho DD, Kwong PD, Dekosky BJ. Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. Front Immunol 2022;13:977064. [DOI: 10.3389/fimmu.2022.977064] [Reference Citation Analysis]
17 Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, Nakka K, Shir-mohammadi K, St-denis-bissonnette F, Tamblyn L, Vranjkovic A, Wood LC, Booth R, Buchan CA, Crawley AM, Little J, Mcguinty M, Saginur R, Langlois M, Cooper CL. Cohort profile: S top the Spread Ottawa (SSO) a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. BMJ Open 2022;12:e062187. [DOI: 10.1136/bmjopen-2022-062187] [Reference Citation Analysis]
18 Alharbi AA, Alshomrani MK, Alharbi AA, Almaeen AH, Alasiri S, Al-omari A, Alishat I, Dolgom S. Immunoglobulin Rapid Test Sensitivity in PCR-Positive COVID-19 Patients. Dr Sulaiman Al Habib Med J 2022;4:153-158. [DOI: 10.1007/s44229-022-00014-x] [Reference Citation Analysis]
19 Hajissa K, Mussa A, Karobari MI, Abbas MA, Ibrahim IK, Assiry AA, Iqbal A, Alhumaid S, Mutair AA, Rabaan AA, Messina P, Scardina GA. The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. Vaccines 2022;10:1346. [DOI: 10.3390/vaccines10081346] [Reference Citation Analysis]
20 Vujkovic-Cvijin I, Welles HC, Ha CWY, Huq L, Mistry S, Brenchley JM, Trinchieri G, Devkota S, Belkaid Y. The systemic anti-microbiota IgG repertoire can identify gut bacteria that translocate across gut barrier surfaces. Sci Transl Med 2022;14:eabl3927. [PMID: 35976997 DOI: 10.1126/scitranslmed.abl3927] [Reference Citation Analysis]
21 He WT, Yuan M, Callaghan S, Musharrafieh R, Song G, Silva M, Beutler N, Lee WH, Yong P, Torres JL, Melo M, Zhou P, Zhao F, Zhu X, Peng L, Huang D, Anzanello F, Ricketts J, Parren M, Garcia E, Ferguson M, Rinaldi W, Rawlings SA, Nemazee D, Smith DM, Briney B, Safonova Y, Rogers TF, Dan JM, Zhang Z, Weiskopf D, Sette A, Crotty S, Irvine DJ, Ward AB, Wilson IA, Burton DR, Andrabi R. Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Sci Transl Med 2022;14:eabl9605. [PMID: 35947674 DOI: 10.1126/scitranslmed.abl9605] [Reference Citation Analysis]
22 Bagno FF, Sérgio SA, Figueiredo MM, Godoi LC, Andrade LA, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AG, Durigon EL, Gazzinelli RT, Teixeira SM, Fernandes APS, da Fonseca FG. DUPLICATE: DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19. Journal of Clinical Virology Plus 2022. [DOI: 10.1016/j.jcvp.2022.100103] [Reference Citation Analysis]
23 Bagno FF, Sérgio SA, Figueiredo MM, Godoi LC, Andrade LA, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AG, Durigon EL, Gazzinelli RT, Teixeira SM, Fernandes APS, da Fonseca FG. Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19. Journal of Clinical Virology Plus 2022;2:100101. [DOI: 10.1016/j.jcvp.2022.100101] [Reference Citation Analysis]
24 Patel H, McArdle A, Seaby E, Levin M, Whittaker E. The immunopathogenesis of SARS-CoV-2 infection in children: diagnostics, treatment and prevention. Clin Transl Immunology 2022;11:e1405. [PMID: 35903804 DOI: 10.1002/cti2.1405] [Reference Citation Analysis]
25 Luvira V, Leaungwutiwong P, Thippornchai N, Thawornkuno C, Chatchen S, Chancharoenthana W, Tandhavanant S, Muangnoicharoen S, Piyaphanee W, Chantratita N. False Positivity of Anti-SARS-CoV-2 Antibodies in Patients with Acute Tropical Diseases in Thailand. TropicalMed 2022;7:132. [DOI: 10.3390/tropicalmed7070132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sherwani S, Khan MWA, Mallik A, Khan M, Saleem M, Raafat M, Shati AA, Alam N. Seroprevalence of Anti-S1-RBD Antibodies in Pre-pandemic and Pandemic Subjects From Hail Region, KSA. Front Public Health 2022;10:874741. [PMID: 35757607 DOI: 10.3389/fpubh.2022.874741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Bold D, Roman-Sosa G, Gaudreault NN, Zayat B, Pogranichniy RM, Richt JA. Development of an Indirect ELISA for the Detection of SARS-CoV-2 Antibodies in Cats. Front Vet Sci 2022;9:864884. [PMID: 35754530 DOI: 10.3389/fvets.2022.864884] [Reference Citation Analysis]
28 Lv H, So RTY, Teo QW, Yuan M, Liu H, Lee CD, Yip GK, Ng WW, Wilson IA, Peiris M, Wu NC, Mok CKP. Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization. Viruses 2022;14:1382. [DOI: 10.3390/v14071382] [Reference Citation Analysis]
29 Lino A, Cardoso MA, Gonçalves HMR, Martins-lopes P. SARS-CoV-2 Detection Methods. Chemosensors 2022;10:221. [DOI: 10.3390/chemosensors10060221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Rotondo JC, Martini F, Maritati M, Caselli E, Gallenga CE, Guarino M, De Giorgio R, Mazziotta C, Tramarin ML, Badiale G, Tognon M, Contini C. Advanced Molecular and Immunological Diagnostic Methods to Detect SARS-CoV-2 Infection. Microorganisms 2022;10:1193. [PMID: 35744711 DOI: 10.3390/microorganisms10061193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
31 Mitchell KF, Carlson CM, Nace D, Wakeman BS, Drobeniuc J, Niemeyer GP, Werner B, Hoffmaster AR, Satheshkumar PS, Schuh AJ, Udhayakumar V, Rogier E. Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2. Microbiol Spectr 2022;:e0105422. [PMID: 35647696 DOI: 10.1128/spectrum.01054-22] [Reference Citation Analysis]
32 Tut G, Lancaster T, Butler MS, Sylla P, Spalkova E, Bone D, Kaur N, Bentley C, Amin U, Jadir AT, Hulme S, Ayodel M, Dowell AC, Pearce H, Zuo J, Margielewska-davies S, Verma K, Nicol S, Begum J, Jinks E, Tut E, Bruton R, Krutikov M, Shrotri M, Giddings R, Azmi B, Fuller C, Irwin-singer A, Hayward A, Copas A, Shallcross L, Moss P. Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection. Nat Aging 2022;2:536-547. [DOI: 10.1038/s43587-022-00224-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kakos CD, Ziogas IA, Tsoulfas G. Pediatric transplantation during the COVID-19 pandemic. World J Transplant 2022; 12(5): 88-99 [DOI: 10.5500/wjt.v12.i5.88] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Smit WL, van Tol S, van der Wal S, van Vulpen F, la Grouw S, van Lelyveld L, Limonard G, Bossink A, Godeke GJ, Shrestha S, Reimerink J, Eggink D, Reusken C, Heron M, Thijsen S. Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19. Front Immunol 2022;13:839367. [PMID: 35355988 DOI: 10.3389/fimmu.2022.839367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, Abe KT, Wang JH, Pasculescu A, Maltseva M, Rocheleau L, Pelchat M, Fazel-Zarandi M, Iskilova M, Barrios-Rodiles M, Bennett L, Yau K, Cholette F, Mesa C, Li AX, Paterson A, Hladunewich MA, Goodwin PJ, Wrana JL, Drews SJ, Mubareka S, McGeer AJ, Kim J, Langlois MA, Gingras AC, Durocher Y. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunology 2022;11:e1380. [PMID: 35356067 DOI: 10.1002/cti2.1380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
36 Salih BA. The effectiveness of the immune responses to SARS-CoV-2. Reviews in Medical Microbiology 2022;33:92-99. [DOI: 10.1097/mrm.0000000000000306] [Reference Citation Analysis]
37 Chai M, Guo Y, Yang L, Li J, Liu S, Chen L, Shen Y, Yang Y, Wang Y, Xu L, Yu C. A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain. Brief Bioinform 2022:bbac070. [PMID: 35362510 DOI: 10.1093/bib/bbac070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hancock TJ, Hickman P, Kazerooni N, Kennedy M, Kania SA, Dennis M, Szafranski N, Gerhold R, Su C, Masi T, Smith S, Sparer TE. Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain. J Virol 2022;:e0025022. [PMID: 35352999 DOI: 10.1128/jvi.00250-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chan MMH, Leung K, Zhang RRQ, Liu D, Fan Y, Khong MKW, Tam AR, Chen H, Yuen K, Hung IFN, Chan K, Perez DR. Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test. Microbiol Spectr. [DOI: 10.1128/spectrum.00993-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 An H, Eun M, Yi J, Park J. CRESSP: a comprehensive pipeline for prediction of immunopathogenic SARS-CoV-2 epitopes using structural properties of proteins. Brief Bioinform 2022:bbac056. [PMID: 35226074 DOI: 10.1093/bib/bbac056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shahbaz FF, Martins RS, Umair A, Ukrani RD, Jabeen K, Sohail MR, Khan E. A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19. Clin Med Insights Pediatr 2022;16:11795565221075319. [PMID: 35197719 DOI: 10.1177/11795565221075319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Dhar BC. Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic. Anal Bioanal Chem 2022. [PMID: 35211785 DOI: 10.1007/s00216-022-03918-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
43 Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science 2022;375:eabl6251. [PMID: 34855508 DOI: 10.1126/science.abl6251] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 29.0] [Reference Citation Analysis]
44 Davoust B, Guérin P, Orain N, Fligny C, Flirden F, Fenollar F, Mediannikov O, Edouard S. Evidence of antibodies against SARS-CoV-2 in wild mustelids from Brittany (France).. [DOI: 10.1101/2022.01.20.477038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Rosenfeld AB, Shen EQL, Melendez M, Mishra N, Lipkin WI, Racaniello VR. Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses. mBio 2022;:e0366021. [PMID: 35038922 DOI: 10.1128/mbio.03660-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Peiris M, Cheng S, Mok CKP, Leung Y, Ng S, Chan K, Ko F, Yiu K, Lam B, Lau E, Chan K, Luk L, Li J, Tsang L, Poon L, Chen C, Hui D. Neutralizing antibody titres to SARS-CoV-2 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted with mRNA BNT162b2 or inactivated CoronaVac vaccines. Res Sq 2022:rs. [PMID: 35018372 DOI: 10.21203/rs.3.rs-1207071/v1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
47 Laroche A, Orsini Delgado ML, Chalopin B, Cuniasse P, Dubois S, Sierocki R, Gallais F, Debroas S, Bellanger L, Simon S, Maillère B, Nozach H. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift. MAbs 2022;14:2076775. [PMID: 35593235 DOI: 10.1080/19420862.2022.2076775] [Reference Citation Analysis]
48 Bastug A, Bodur H. SARS-CoV-2 Infection and Antibody-Dependent Enhancement. Understanding COVID-19: The Role of Computational Intelligence 2022. [DOI: 10.1007/978-3-030-74761-9_5] [Reference Citation Analysis]
49 Abolmaali SS, Alimardani V, Farahavar G, Najafi H, Shafiee M, Tanideh N, Tamaddon AM, Ahadian S. Nanotechnology-based approaches against COVID-19. Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance 2022. [DOI: 10.1016/b978-0-323-90792-7.00012-9] [Reference Citation Analysis]
50 Errico JM, Adams LJ, Fremont DH. Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology 2022. [DOI: 10.1016/bs.ai.2022.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Bhardwaj M, Kakkar P. Current clinical testing approach of COVID. Sensing Tools and Techniques for COVID-19 2022. [DOI: 10.1016/b978-0-323-90280-9.00003-1] [Reference Citation Analysis]
52 Hancock TJ, Hickman P, Kazerooni N, Kennedy M, Kania SA, Dennis M, Szafranski N, Gerhold R, Su C, Masi T, Smith S, Sparer TE. Possible Cross Reactivity of Feline and White-tailed Deer Antibodies Against the SARS-CoV-2 Receptor Binding Domain.. [DOI: 10.1101/2021.12.17.473265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Sypabekova M, Tosi D, Vangelista L. Perspectives on Assembling Coronavirus Spikes on Fiber Optics to Reveal Broadly Recognizing Antibodies and Generate a Universal Coronavirus Detector. Front Bioeng Biotechnol 2021;9:637715. [PMID: 34900951 DOI: 10.3389/fbioe.2021.637715] [Reference Citation Analysis]
54 Laroche A, Orsini Delgado ML, Cuniasse P, Dubois S, Sierocki R, Gallais F, Debroas S, Bellanger L, Simon S, Maillère B, Nozach H. Deep Mutational Engineering of broadly-neutralizing and picomolar affinity nanobodies to accommodate SARS-CoV-1 & 2 antigenic polymorphism.. [DOI: 10.1101/2021.12.07.471597] [Reference Citation Analysis]
55 [DOI: 10.1109/csde53843.2021.9718501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Galipeau Y, Siragam V, Laroche G, Marion E, Greig M, McGuinty M, Booth RA, Durocher Y, Cuperlovic-Culf M, Bennett SAL, Crawley AM, Giguère PM, Cooper C, Langlois MA. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine 2021;74:103700. [PMID: 34861490 DOI: 10.1016/j.ebiom.2021.103700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
57 Shahgolzari M, Yavari A, Arjeini Y, Miri SM, Darabi A, Mozaffari Nejad AS, Keshavarz M. Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Rep 2021;25:101417. [PMID: 34778602 DOI: 10.1016/j.genrep.2021.101417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
58 Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Mol Biomed 2021;2:1. [PMID: 34766001 DOI: 10.1186/s43556-020-00015-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
59 Li H, Zhang Y, Li D, Deng YQ, Xu H, Zhao C, Liu J, Wen D, Zhao J, Li Y, Wu Y, Liu S, Liu J, Hao J, Yuan F, Duo S, Qin CF, Zheng A. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct Target Ther 2021;6:389. [PMID: 34759261 DOI: 10.1038/s41392-021-00797-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
60 Shen Y, Anwar TB, Mulchandani A. Current status, advances, challenges and perspectives on biosensors for COVID-19 diagnosis in resource-limited settings. Sensors and Actuators Reports 2021;3:100025. [DOI: 10.1016/j.snr.2021.100025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
61 Aguilar-Bretones M, Westerhuis BM, Raadsen MP, de Bruin E, Chandler FD, Okba NM, Haagmans BL, Langerak T, Endeman H, van den Akker JP, Gommers DA, van Gorp EC, GeurtsvanKessel CH, de Vries RD, Fouchier RA, Rockx BH, Koopmans MP, van Nierop GP. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. J Clin Invest 2021;131:e150613. [PMID: 34499051 DOI: 10.1172/JCI150613] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
62 Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, Abe KT, Wang JH, Pasculescu A, Maltseva M, Rocheleau L, Pelchat M, Fazel-zarandi M, Iskilova M, Barrios-rodiles M, Bennett L, Yau K, Cholette F, Mesa C, Li AX, Paterson A, Hladunewich MA, Goodwin PJ, Wrana JL, Drews SJ, Mubareka S, Mcgeer AJ, Kim J, Langlois M, Gingras A, Durocher Y. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination.. [DOI: 10.1101/2021.10.25.21265476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
63 Murugan C, Ramamoorthy S, Kuppuswamy G, Murugan RK, Sivalingam Y, Sundaramurthy A. COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. Int J Biol Macromol 2021:S0141-8130(21)02301-1. [PMID: 34710479 DOI: 10.1016/j.ijbiomac.2021.10.144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
64 Li T, Cai H, Zhao Y, Li Y, Lai Y, Yao H, Liu LD, Sun Z, van Vlissingen MF, Kuiken T, GeurtsvanKessel CH, Zhang N, Zhou B, Lu L, Gong Y, Qin W, Mondal M, Duan B, Xu S, Richard AS, Raoul H, Chen J, Xu C, Wu L, Zhou H, Huang Z, Zhang X, Li J, Wang Y, Bi Y, Rockx B, Chen J, Meng FL, Lavillette D, Li D. Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. EMBO Mol Med 2021;:e14544. [PMID: 34672091 DOI: 10.15252/emmm.202114544] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
65 K B M, Nayar SA, P V M. Vaccine and vaccination as a part of human life: In view of COVID-19. Biotechnol J 2021;:e2100188. [PMID: 34665927 DOI: 10.1002/biot.202100188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wang T, Fang X, Wen T, Liu J, Zhai Z, Wang Z, Meng J, Yang Y, Wang C, Xu H. Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2. J Med Chem 2021;64:14887-94. [PMID: 34533959 DOI: 10.1021/acs.jmedchem.1c01440] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
67 Dalle Carbonare L, Valenti MT, Bisoffi Z, Piubelli C, Pizzato M, Accordini S, Mariotto S, Ferrari S, Minoia A, Bertacco J, Li Vigni V, Dorelli G, Crisafulli E, Alberti D, Masin L, Tiberti N, Longoni SS, Lopalco L, Beretta A, Zipeto D. Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve. Commun Med 2021;1. [DOI: 10.1038/s43856-021-00039-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
68 Cimolai N. Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clin Hematol Int 2021;3:47-68. [PMID: 34595467 DOI: 10.2991/chi.k.210328.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Majolo F, Silva GLD, Vieira L, Anli C, Timmers LFSM, Laufer S, Goettert MI. Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals (Basel) 2021;14:933. [PMID: 34577633 DOI: 10.3390/ph14090933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
70 Kobayashi K, Tachibana M, Tsutsumi Y. Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. Innate Immun 2021;27:423-36. [PMID: 34521229 DOI: 10.1177/17534259211043159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
71 Jamiruddin R, Haq A, Khondoker MU, Ali T, Ahmed F Md, Khandker SS, Jawad I, Hossain R, Ahmed S, Rahman SR, Mustafi M, Kaitsuka T, Mie M, Tomizawa K, Kobatake E, Haque M, Adnan N. Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh. Expert Rev Vaccines 2021;:1-10. [PMID: 34503369 DOI: 10.1080/14760584.2021.1977630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
72 Tan CCS, Owen CJ, Tham CYL, Bertoletti A, van Dorp L, Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. Infect Genet Evol 2021;95:105075. [PMID: 34509646 DOI: 10.1016/j.meegid.2021.105075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
73 Blanchard-Rohner G, Didierlaurent A, Tilmanne A, Smeesters P, Marchant A. Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. Vaccines (Basel) 2021;9:1002. [PMID: 34579240 DOI: 10.3390/vaccines9091002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
74 Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, Makayotto L, Nasimiyu C, Gunn BM, Nyawanda B, Oluga O, Ngunu C, Mirieri H, Gachohi J, Marwanga D, Munywoki PK, Odhiambo D, Alando MD, Breiman RF, Anzala O, Njenga MK, Bulterys M, Herman-Roloff A, Osoro E. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya. Int J Infect Dis 2021;112:25-34. [PMID: 34481966 DOI: 10.1016/j.ijid.2021.08.062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
75 Çelik Ekinci S, Şaylan B. The rate and associated factors with antibody response in patients with COVID-19 infection. Journal of Surgery and Medicine 2021;5:832-837. [DOI: 10.28982/josam.867695] [Reference Citation Analysis]
76 Daneshyar Z, Rahimi N, Clinical Research Development Unit, Imamsajad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran, Clinical Research Development Unit, Imamsajad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran. A Review on Laboratory Findings of Patients with COVID-19 Infection. J Clinic Care Skill 2021;2:129-138. [DOI: 10.52547/jccs.2.3.129] [Reference Citation Analysis]
77 Huang Y, Xie J, Guo Y, Sun W, He Y, Liu K, Yan J, Tao A, Zhong N. SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses. Healthcare (Basel) 2021;9:1132. [PMID: 34574906 DOI: 10.3390/healthcare9091132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Yang S, Pan X, Yuan D, Zeng P, Jia P. Cross-disciplinary approaches to assist with nucleic acid testing for SARS-CoV-2. Appl Microbiol Biotechnol 2021;105:6291-9. [PMID: 34423408 DOI: 10.1007/s00253-021-11498-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Vujkovic-cvijin I, Welles H, Ha CW, Huq L, Mistry S, Brenchley JM, Trinchieri G, Devkota S, Belkaid Y. Systemic IgG repertoire as a biomarker for translocating gut microbiota members.. [DOI: 10.1101/2021.08.17.456549] [Reference Citation Analysis]
80 Filippatos F, Tatsi EB, Michos A. Immune response to SARS-CoV-2 in children: A review of the current knowledge. Pediatr Investig 2021;:e12283. [PMID: 34540321 DOI: 10.1002/ped4.12283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
81 Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L; CV-NCOV-001 Study Group. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr 2021. [PMID: 34378087 DOI: 10.1007/s00508-021-01922-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 34.0] [Reference Citation Analysis]
82 Sampson AT, Heeney J, Cantoni D, Ferrari M, Sans MS, George C, Di Genova C, Mayora Neto M, Einhauser S, Asbach B, Wagner R, Baxendale H, Temperton N, Carnell G. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses 2021;13:1579. [PMID: 34452443 DOI: 10.3390/v13081579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Migliorini F, Torsiello E, Spiezia F, Oliva F, Tingart M, Maffulli N. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature. Eur J Med Res 2021;26:84. [PMID: 34344463 DOI: 10.1186/s40001-021-00563-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 27.0] [Reference Citation Analysis]
84 Malik YS, Kumar P, Ansari MI, Hemida MG, El Zowalaty ME, Abdel-Moneim AS, Ganesh B, Salajegheh S, Natesan S, Sircar S, Safdar M, Vinodhkumar OR, Duarte PM, Patel SK, Klein J, Rahimi P, Dhama K. SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development. Front Mol Biosci 2021;8:607886. [PMID: 34395515 DOI: 10.3389/fmolb.2021.607886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
85 Galipeau Y, Siragam V, Laroche G, Marion E, Greig M, Mcguinty M, Booth RA, Durocher Y, Cuperlovic-culf M, Bennett SA, Crawley AM, Giguère PM, Cooper C, Langlois M. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.. [DOI: 10.1101/2021.07.16.21260079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Li L, Gao M, Li J, Zu S, Wang Y, Chen C, Wan D, Duan J, Aliyari R, Wang J, Zhang J, Jin Y, Huang W, Jin X, Shi M, Wang Y, Qin CF, Yang H, Cheng G. Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients. Small Methods 2021;5:2100058. [PMID: 34514088 DOI: 10.1002/smtd.202100058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Jia L, Weng S, Wu J, Tian X, Zhang Y, Wang X, Wang J, Yan D, Wang W, Fang F, Zhu Z, Qiu C, Zhang W, Xu Y, Wan Y. Pre-existing antibodies targeting a linear epitope on SARS-CoV-2 S2 cross-reacted with commensal gut bacteria and shaped vaccine induced immunity.. [DOI: 10.1101/2021.07.13.21260404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 S N N, B N R, C P, K S S, Ramakrishnappa T, B T K, S M J, M M, N A, Yallappa, D DP, T V R, E G, Bagoji M, Chandaragi SS. SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study. Mater Today Proc 2021. [PMID: 34307057 DOI: 10.1016/j.matpr.2021.07.163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, Huang W, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z, Zhang L, Wang X, Zhang Z. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun 2021;12:4210. [PMID: 34244522 DOI: 10.1038/s41467-021-24514-w] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 39.0] [Reference Citation Analysis]
90 Kumavath R, Barh D, Andrade BS, Imchen M, Aburjaile FF, Ch A, Rodrigues DLN, Tiwari S, Alzahrani KJ, Góes-Neto A, Weener ME, Ghosh P, Azevedo V. The Spike of SARS-CoV-2: Uniqueness and Applications. Front Immunol 2021;12:663912. [PMID: 34305894 DOI: 10.3389/fimmu.2021.663912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
91 Anft M, Blazquez-Navarro A, Stervbo U, Skrzypczyk S, Witzke O, Wirth R, Choi M, Hugo C, Reinke P, Meister TL, Steinmann E, Pfaender S, Schenker P, Viebahn R, Westhoff TH, Babel N. Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. J Nephrol 2021;34:1025-37. [PMID: 34228322 DOI: 10.1007/s40620-021-01092-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ivanov A, Semenova E. Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection. J Med Virol 2021;93:5953-60. [PMID: 34185312 DOI: 10.1002/jmv.27166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
93 Bagno FF, Sérgio SAR, Figueiredo MM, Godoi LC, Andrade LAF, Salazar NC, Soares CP, Aguiar A, Almeida FJ, da Silva ED, Ferreira AGP, Durigon EL, Gazzinelli RT, Teixeira SMR, Fernandes APSM, da Fonseca FG. DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19.. [DOI: 10.1101/2021.06.23.21259392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Lv H, Tsang OT, So RTY, Wang Y, Yuan M, Liu H, Yip GK, Teo QW, Lin Y, Liang W, Wang J, Ng WW, Wilson IA, Peiris JSM, Wu NC, Mok CKP. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. Eur J Immunol 2021;51:2296-305. [PMID: 34089541 DOI: 10.1002/eji.202149234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
95 Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, Yang ES, Chu HY, Torres JL, Ozorowski G, Ward AB, Whaley RE, Cohen KW, Pancera M, McElrath MJ, Englund JA, Finzi A, Suthar MS, McGuire AT, Stamatatos L. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep 2021;36:109353. [PMID: 34237283 DOI: 10.1016/j.celrep.2021.109353] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 53.0] [Reference Citation Analysis]
96 Heffron AS, McIlwain SJ, Amjadi MF, Baker DA, Khullar S, Armbrust T, Halfmann PJ, Kawaoka Y, Sethi AK, Palmenberg AC, Shelef MA, O'Connor DH, Ong IM. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol 2021;19:e3001265. [PMID: 34143766 DOI: 10.1371/journal.pbio.3001265] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
97 Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, Amanat F, Jiang K, Krammer F, Carratala J, García-Sastre A. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun 2021;12:3781. [PMID: 34145263 DOI: 10.1038/s41467-021-23977-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 75.0] [Reference Citation Analysis]
98 Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, Biswas S. Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests. J Med Microbiol 2021;70. [PMID: 34110279 DOI: 10.1099/jmm.0.001369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
99 Shang Z, Chan SY, Liu WJ, Li P, Huang W. Recent Insights into Emerging Coronavirus: SARS-CoV-2. ACS Infect Dis 2021;7:1369-88. [PMID: 33296169 DOI: 10.1021/acsinfecdis.0c00646] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
100 Rezvani Ghomi E, Khosravi F, Mohseni-M A, Nourbakhsh N, Haji Mohammad Hoseini M, Singh S, Hedenqvist MS, Ramakrishna S. A collection of the novel coronavirus (COVID-19) detection assays, issues, and challenges. Heliyon 2021;7:e07247. [PMID: 34124407 DOI: 10.1016/j.heliyon.2021.e07247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Fedry J, Hurdiss DL, Wang C, Li W, Obal G, Drulyte I, Du W, Howes SC, van Kuppeveld FJM, Förster F, Bosch BJ. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Sci Adv 2021;7:eabf5632. [PMID: 33958322 DOI: 10.1126/sciadv.abf5632] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
102 Kombe Kombe AJ, Zahid A, Mohammed A, Shi R, Jin T. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. Front Mol Biosci 2021;8:670815. [PMID: 34136533 DOI: 10.3389/fmolb.2021.670815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
103 Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, Viscardi M, Brandi S, Cerino P, Zambrano N, Zollo M, De Lorenzo C. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep 2021;11:11046. [PMID: 34040046 DOI: 10.1038/s41598-021-90348-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
104 Luo Y, Wang J, Zhang M, Wang Q, Chen R, Wang X, Wang H. COVID-19-another influential event impacts on laboratory medicine management. J Clin Lab Anal 2021;35:e23804. [PMID: 34032325 DOI: 10.1002/jcla.23804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE Jr, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med 2021;2:100313. [PMID: 34056628 DOI: 10.1016/j.xcrm.2021.100313] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 34.0] [Reference Citation Analysis]
106 Schoenle MV, Li Y, Yuan M, Clarkson MW, Wilson IA, Peti W, Page R. NMR Based SARS-CoV-2 Antibody Screening. J Am Chem Soc 2021;143:7930-4. [PMID: 34018723 DOI: 10.1021/jacs.1c03945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
107 Tseng WP, Wu JL, Wu CC, Kuo KT, Lin CH, Chung MY, Lee YF, Yang BJ, Huang CH, Chen SY, Yu CJ, Chen SC, Hsueh PR. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003. Front Immunol 2021;12:626609. [PMID: 34084161 DOI: 10.3389/fimmu.2021.626609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM, Jahanshahi-Anbuhi S. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clin Microbiol Rev 2021;34:e00228-20. [PMID: 33980687 DOI: 10.1128/CMR.00228-20] [Cited by in Crossref: 66] [Cited by in F6Publishing: 77] [Article Influence: 66.0] [Reference Citation Analysis]
109 De Nicolò A, Avataneo V, Cusato J, Palermiti A, Mula J, De Vivo E, Antonucci M, Bonora S, Calcagno A, Di Perri G, De Rosa FG, D'Avolio A. Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. Diagnostics (Basel) 2021;11:869. [PMID: 34065954 DOI: 10.3390/diagnostics11050869] [Reference Citation Analysis]
110 Colitti B, Bertolotti L, Mannelli A, Ferrara G, Vercelli A, Grassi A, Trentin C, Paltrinieri S, Nogarol C, Decaro N, Brocchi E, Rosati S. Cross-Sectional Serosurvey of Companion Animals Housed with SARS-CoV-2-Infected Owners, Italy. Emerg Infect Dis 2021;27:1919-22. [PMID: 33974535 DOI: 10.3201/eid2707.203314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
111 Montague Z, Lv H, Otwinowski J, DeWitt WS, Isacchini G, Yip GK, Ng WW, Tsang OT, Yuan M, Liu H, Wilson IA, Peiris JSM, Wu NC, Nourmohammad A, Mok CKP. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Rep 2021;35:109173. [PMID: 33991510 DOI: 10.1016/j.celrep.2021.109173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 23.0] [Reference Citation Analysis]
112 Holenya P, Lange PJ, Reimer U, Woltersdorf W, Panterodt T, Glas M, Wasner M, Eckey M, Drosch M, Hollidt JM, Naumann M, Kern F, Wenschuh H, Lange R, Schnatbaum K, Bier FF. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. Eur J Immunol 2021;51:1839-49. [PMID: 33772767 DOI: 10.1002/eji.202049101] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
113 Asif M, Xu Y, Xiao F, Sun Y. Diagnosis of COVID-19, vitality of emerging technologies and preventive measures. Chem Eng J 2021;423:130189. [PMID: 33994842 DOI: 10.1016/j.cej.2021.130189] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
114 Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohé SB, Wiersinga WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T, Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R, Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martín JF, Rubio I. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021;9:622-42. [PMID: 33965003 DOI: 10.1016/S2213-2600(21)00218-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 129] [Article Influence: 181.0] [Reference Citation Analysis]
115 Ryder SP, Morgan BR, Coskun P, Antkowiak K, Massi F. Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome. Evol Bioinform Online 2021;17:11769343211014167. [PMID: 34017166 DOI: 10.1177/11769343211014167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
116 Matthews MM, Kim TG, Shibata S, Shibata N, Butcher C, Hyun J, Kim KY, Robb T, Jheng SS, Narita M, Mori T, Collins M, Wolf M. COVID-19 serological survey using micro blood sampling. Sci Rep 2021;11:9475. [PMID: 33947894 DOI: 10.1038/s41598-021-88850-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
117 Noori M, Nejadghaderi SA, Rezaei N. "Original antigenic sin": A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants. Infect Control Hosp Epidemiol 2021;:1-2. [PMID: 33938416 DOI: 10.1017/ice.2021.199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
118 Dwyer CJ, Cloud CA, Wang C, Heidt P, Chakraborty P, Duke TF, McGue S, Jeffcoat B, Dunne J, Johnson L, Choi S, Nahhas GJ, Gandy AS, Babic N, Nolte FS, Howe P, Ogretmen B, Gangaraju VK, Tomlinson S, Madden B, Bridges T, Flume PA, Wrangle J, Rubinstein MP, Baliga PK, Nadig SN, Mehrotra S. Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. iScience 2021;24:102489. [PMID: 33969281 DOI: 10.1016/j.isci.2021.102489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
119 Pagadala NS, Landi A, Maturu P, Tuszynski J. In silico identification of RBD subdomain of spike protein from Pro322-Thr581 for applications in vaccine development against SARS-CoV2. J Mol Struct 2021;1240:130534. [PMID: 33967342 DOI: 10.1016/j.molstruc.2021.130534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Chen Z, Xu W, Ma W, Shi X, Li S, Hao M, Fang Y, Zhang L. Clinical laboratory evaluation of COVID-19. Clin Chim Acta 2021;519:172-82. [PMID: 33939954 DOI: 10.1016/j.cca.2021.04.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
121 Veenhuis RT, Zeiss CJ. Animal Models of COVID-19 II. Comparative Immunology. ILAR J 2021:ilab010. [PMID: 33914873 DOI: 10.1093/ilar/ilab010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
122 Bubonja-Šonje M, Batičić L, Abram M, Cekinović Grbeša Đ. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies. J Virol Methods 2021;293:114173. [PMID: 33930473 DOI: 10.1016/j.jviromet.2021.114173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
123 Jia W, Wang J, Sun B, Zhou J, Shi Y, Zhou Z. The Mechanisms and Animal Models of SARS-CoV-2 Infection. Front Cell Dev Biol 2021;9:578825. [PMID: 33987176 DOI: 10.3389/fcell.2021.578825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
124 Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G Jr, Arumugaswami V, Fries BC, Arditi M, Bahar I. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. Structure 2021:S0969-2126(21)00121-0. [PMID: 33930306 DOI: 10.1016/j.str.2021.04.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
125 Min L, Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Front Mol Biosci 2021;8:671633. [PMID: 33968996 DOI: 10.3389/fmolb.2021.671633] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 48.0] [Reference Citation Analysis]
126 Hossain MZ, Uddin MB, Ahmed KA. CovidEnvelope: A Fast Automated Approach to Diagnose COVID-19 from Cough Signals.. [DOI: 10.1101/2021.04.16.21255630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
127 Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan D, Shoham S, Quinn TC, Larman HB, Casadevall A, Pekosz A, Redd AD, Tobian AAR, Ackerman ME. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. mBio 2021;12:e00765-21. [PMID: 33879585 DOI: 10.1128/mBio.00765-21] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 33.0] [Reference Citation Analysis]
128 Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol 2021;12:633184. [PMID: 33936045 DOI: 10.3389/fimmu.2021.633184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 53.0] [Reference Citation Analysis]
129 Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rd, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res 2021;128:1214-36. [PMID: 33856918 DOI: 10.1161/CIRCRESAHA.121.317997] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 95.0] [Reference Citation Analysis]
130 Malik YS, Ansari MI, Kattoor JJ, Kaushik R, Sircar S, Subbaiyan A, Tiwari R, Dhama K, Ghosh S, Tomar S, Zhang KYJ. Evolutionary and codon usage preference insights into spike glycoprotein of SARS-CoV-2. Brief Bioinform 2021;22:1006-22. [PMID: 33377145 DOI: 10.1093/bib/bbaa383] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
131 Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, Chen H, Ren L, Gu X, Wang G, Wang C, Dong X, Wu C, Han L, Wang Y, Fan G, Zou X, Li H, Xu J, Jin Q, Cao B, Wang J. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect 2021;10:664-76. [PMID: 33734013 DOI: 10.1080/22221751.2021.1905488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 47.0] [Reference Citation Analysis]
132 Guevara-Hoyer K, Fuentes-Antrás J, De la Fuente-Muñoz E, Rodríguez de la Peña A, Viñuela M, Cabello-Clotet N, Estrada V, Culebras E, Delgado-Iribarren A, Martínez-Novillo M, Torrejón MJ, Pérez de Diego R, Fernández-Arquero M, Ocaña A, Pérez-Segura P, Sánchez-Ramón S. Serological Tests in the Detection of SARS-CoV-2 Antibodies. Diagnostics (Basel) 2021;11:678. [PMID: 33918840 DOI: 10.3390/diagnostics11040678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
133 Khadangi F, Forgues AS, Tremblay-Pitre S, Dufour-Mailhot A, Henry C, Boucher M, Beaulieu MJ, Morissette M, Fereydoonzad L, Brunet D, Robichaud A, Bossé Y. Intranasal versus intratracheal exposure to lipopolysaccharides in a murine model of acute respiratory distress syndrome. Sci Rep 2021;11:7777. [PMID: 33833346 DOI: 10.1038/s41598-021-87462-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
134 Dheyab MA, Khaniabadi PM, Aziz AA, Jameel MS, Mehrdel B, Oglat AA, Khaleel HA. Focused role of nanoparticles against COVID-19: Diagnosis and treatment. Photodiagnosis Photodyn Ther 2021;34:102287. [PMID: 33836276 DOI: 10.1016/j.pdpdt.2021.102287] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
135 Montague Z, Lv H, Otwinowski J, DeWitt WS, Isacchini G, Yip GK, Ng WW, Tsang OT, Yuan M, Liu H, Wilson IA, Peiris JSM, Wu NC, Nourmohammad A, Mok CKP. Dynamics of B-cell repertoires and emergence of cross-reactive responses in COVID-19 patients with different disease severity. medRxiv 2021:2020. [PMID: 32699862 DOI: 10.1101/2020.07.13.20153114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Sereda TG, Kostarev SN, Kochetova OV. Development of a module for an automated diagnostic system for antibodies G and M. J Phys : Conf Ser 2021;1889:052019. [DOI: 10.1088/1742-6596/1889/5/052019] [Reference Citation Analysis]
137 To KK, Sridhar S, Chiu KH, Hung DL, Li X, Hung IF, Tam AR, Chung TW, Chan JF, Zhang AJ, Cheng VC, Yuen KY. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect 2021;10:507-35. [PMID: 33666147 DOI: 10.1080/22221751.2021.1898291] [Cited by in Crossref: 86] [Cited by in F6Publishing: 63] [Article Influence: 86.0] [Reference Citation Analysis]
138 Li C, Zhao H, Cheng L, Wang B. Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19. Drug Des Devel Ther 2021;15:1345-56. [PMID: 33824579 DOI: 10.2147/DDDT.S301173] [Reference Citation Analysis]
139 Liu G, Rusling JF. COVID-19 Antibody Tests and Their Limitations. ACS Sens 2021;6:593-612. [PMID: 33544999 DOI: 10.1021/acssensors.0c02621] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 76.0] [Reference Citation Analysis]
140 Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, Yang ES, Chu HY, Torres JL, Ozorowski G, Ward AB, Whaley RE, Cohen KW, Pancera M, McElrath MJ, Englund JA, Finzi A, Suthar MS, McGuire AT, Stamatatos L. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. bioRxiv 2021:2021. [PMID: 33791692 DOI: 10.1101/2021.03.23.436684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
141 Fotis C, Meimetis N, Tsolakos N, Politou M, Akinosoglou K, Pliaka V, Minia A, Terpos E, Trougakos IP, Mentis A, Marangos M, Panayiotakopoulos G, Dimopoulos MA, Gogos C, Spyridonidis A, Alexopoulos LG. Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Sci Rep 2021;11:6614. [PMID: 33758278 DOI: 10.1038/s41598-021-86035-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
142 Arenas A, Borge C, Carbonero A, Garcia-Bocanegra I, Cano-Terriza D, Caballero J, Arenas-Montes A. Bovine Coronavirus Immune Milk Against COVID-19. Front Immunol 2021;12:637152. [PMID: 33833758 DOI: 10.3389/fimmu.2021.637152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
143 Maneira C, Bermejo PM, Pereira GAG, de Mello FDSB. Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. FEMS Yeast Res 2021;21:foab004. [PMID: 33469649 DOI: 10.1093/femsyr/foab004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Écochard R, Wimba P, Bengehya J, Katchunga PB, Lugwarha S, Oyimangirwe M, Bazeboso JA, Tshilolo L, Longo-Mbenza B, Rabilloud M, Iwaz J, Étard JF, Vanhems P. The COVID-19 pandemic is deepening the health crisis in South Kivu, Democratic Republic of Congo. Int J Infect Dis 2021;105:716-20. [PMID: 33744480 DOI: 10.1016/j.ijid.2021.03.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
145 Kierkegaard P, McLister A, Buckle P. Rapid point-of-care testing for COVID-19: quality of supportive information for lateral flow serology assays. BMJ Open 2021;11:e047163. [PMID: 33741675 DOI: 10.1136/bmjopen-2020-047163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
146 Wood R, Thomson E, Galbraith R, Gribben C, Caldwell D, Bishop J, Reid M, Shah ASV, Templeton K, Goldberg D, Robertson C, Hutchinson SJ, Colhoun HM, McKeigue PM, McAllister DA. Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Arch Dis Child 2021:archdischild-2021-321604. [PMID: 33737319 DOI: 10.1136/archdischild-2021-321604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
147 Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, Widjaja I, van Dieren B, Fernandez-Delgado R, Sola I, Hurdiss DL, Daramola O, Grosveld F, van Kuppeveld FJM, Haagmans BL, Enjuanes L, Drabek D, Bosch BJ. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun 2021;12:1715. [PMID: 33731724 DOI: 10.1038/s41467-021-21968-w] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 82.0] [Reference Citation Analysis]
148 Małecki P, Faltin K, Mania A, Mazur-Melewska K, Cwalińska A, Zawadzka A, Bukowska A, Lisowska K, Graniczna K, Figlerowicz M. Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series. Life (Basel) 2021;11:247. [PMID: 33802763 DOI: 10.3390/life11030247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
149 Yuan Y, Yu L, Jin Z, Wang Y, Gao M, Ding H, Zhuo X, Zhu X, Gao F, Zheng X, Ying G, Xu X, Kong Q, Lu S, Lv H. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020. Front Cell Infect Microbiol 2021;11:650487. [PMID: 33796489 DOI: 10.3389/fcimb.2021.650487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 L'Huillier AG, Danziger-Isakov L, Chaudhuri A, Green M, Michaels MG, M Posfay-Barbe K, van der Linden D, Verma A, McCulloch M, Ardura MI. SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. Pediatr Transplant 2021;25:e13986. [PMID: 33689201 DOI: 10.1111/petr.13986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
151 Seckar T, Lin X, Bose D, Wei Z, Rohrbaugh J, Collman RG, Robertson ES. Detection of Microbial Agents in Oropharyngeal and Nasopharyngeal Samples of SARS-CoV-2 Patients. Front Microbiol 2021;12:637202. [PMID: 33790878 DOI: 10.3389/fmicb.2021.637202] [Reference Citation Analysis]
152 Chau CYC, Chow LLW, Sridhar S, Shih KC. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders. Ophthalmol Ther 2021;10:201-9. [PMID: 33675508 DOI: 10.1007/s40123-021-00338-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
153 Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, McLawhon RW, Voss JE, Nemazee D, Fitzgerald RL. Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. Clin Chem 2021;67:404-14. [PMID: 33084854 DOI: 10.1093/clinchem/hvaa262] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 42.0] [Reference Citation Analysis]
154 Garg P. Convalescent Plasma Therapy: A New Flair of Hope in the Fight Against the Novel Corona Virus Pandemic (COVID-19). Nano LIFE 2021;11:2050004. [DOI: 10.1142/s179398442050004x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Pinals RL, Ledesma F, Yang D, Navarro N, Jeong S, Pak JE, Kuo L, Chuang YC, Cheng YW, Sun HY, Landry MP. Rapid SARS-CoV-2 Spike Protein Detection by Carbon Nanotube-Based Near-Infrared Nanosensors. Nano Lett 2021;21:2272-80. [PMID: 33635655 DOI: 10.1021/acs.nanolett.1c00118] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 63.0] [Reference Citation Analysis]
156 Bell BN, Powell AE, Rodriguez C, Cochran JR, Kim PS. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. Protein Sci 2021;30:716-27. [PMID: 33586288 DOI: 10.1002/pro.4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
157 Yang C, Pan X, Huang Y, Cheng C, Xu X, Wu Y, Xu Y, Shang W, Niu X, Wan Y, Li Z, Zhang R, Liu S, Xiao G, Xu W. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion. Adv Ther (Weinh) 2021;:2000224. [PMID: 33786369 DOI: 10.1002/adtp.202000224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
158 Lv H, Tsang OT, So RTY, Wang Y, Yuan M, Liu H, Yip GK, Teo QW, Lin Y, Liang W, Wang J, Ng WW, Wilson IA, Peiris JSM, Wu NC, Mok CKP. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2.. [DOI: 10.1101/2021.02.17.431722] [Reference Citation Analysis]
159 Piec I, English E, Thomas MA, Dervisevic S, Fraser WD, John WG. Performance of SARS-CoV-2 serology tests: Are they good enough? PLoS One 2021;16:e0245914. [PMID: 33596236 DOI: 10.1371/journal.pone.0245914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
160 Mishra N, Huang X, Joshi S, Guo C, Ng J, Thakkar R, Wu Y, Dong X, Li Q, Pinapati RS, Sullivan E, Caciula A, Tokarz R, Briese T, Lu J, Lipkin WI. Immunoreactive peptide maps of SARS-CoV-2. Commun Biol 2021;4:225. [PMID: 33580175 DOI: 10.1038/s42003-021-01743-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
161 Dyrdak R, Hodcroft EB, Wahlund M, Neher RA, Albert J. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020. J Clin Virol 2021;136:104754. [PMID: 33601153 DOI: 10.1016/j.jcv.2021.104754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
162 Cusenza F, Davino G, D'Alvano T, Argentiero A, Fainardi V, Pisi G, Principi N, Esposito S. Silence of the Lambs: The Immunological and Molecular Mechanisms of COVID-19 in Children in Comparison with Adults. Microorganisms 2021;9:330. [PMID: 33562210 DOI: 10.3390/microorganisms9020330] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
163 Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, Plassmeyer M, Coatney P, Lillard K, Bukhari Z, Kleinberg M, Hayes C, Arditi M, Klapper E, Merin N, Liang BT, Gupta R, Alpan O, Unutmaz D. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun Biol 2021;4:129. [PMID: 33514825 DOI: 10.1038/s42003-021-01649-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 58.0] [Reference Citation Analysis]
164 Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep 2021;34:108737. [PMID: 33545052 DOI: 10.1016/j.celrep.2021.108737] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 32.0] [Reference Citation Analysis]
165 Lagoumintzis G, Chasapis CT, Alexandris N, Kouretas D, Tzartos S, Eliopoulos E, Farsalinos K, Poulas K. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins. Food Chem Toxicol 2021;149:112009. [PMID: 33503469 DOI: 10.1016/j.fct.2021.112009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
166 Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, To EMW, Yen HL, Leung K, Cheng SMS, Chan KH, Chan KCK, Li KC, Saif L, Barrs VR, Wu JT, Sit THC, Poon LLM, Peiris M. Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. J Clin Microbiol 2021;59:e02504-20. [PMID: 33139421 DOI: 10.1128/JCM.02504-20] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 54.0] [Reference Citation Analysis]
167 Kobayashi R, Murai R, Asanuma K, Fujiya Y, Takahashi S. Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen. J Infect Chemother 2021;27:800-7. [PMID: 33546959 DOI: 10.1016/j.jiac.2021.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
168 Cueno ME, Imai K. Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses. Front Med (Lausanne) 2020;7:594439. [PMID: 33585502 DOI: 10.3389/fmed.2020.594439] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
169 Fu Y, Pan Y, Li Z, Li Y. The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis. Front Microbiol 2020;11:603058. [PMID: 33519745 DOI: 10.3389/fmicb.2020.603058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
170 Tavasolian F, Rashidi M, Hatam GR, Jeddi M, Hosseini AZ, Mosawi SH, Abdollahi E, Inman RD. HLA, Immune Response, and Susceptibility to COVID-19. Front Immunol 2020;11:601886. [PMID: 33488597 DOI: 10.3389/fimmu.2020.601886] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 32.0] [Reference Citation Analysis]
171 Heffron AS, McIlwain SJ, Amjadi MF, Baker DA, Khullar S, Sethi AK, Palmenberg AC, Shelef MA, O'Connor DH, Ong IM. The landscape of antibody binding in SARS-CoV-2 infection. bioRxiv 2021:2020. [PMID: 33052349 DOI: 10.1101/2020.10.10.334292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
172 Huergo MAC, Thanh NTK. Current advances in the detection of COVID-19 and evaluation of the humoral response. Analyst 2021;146:382-402. [PMID: 33410826 DOI: 10.1039/d0an01686a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
173 Zheng Y, Larragoite ET, Williams ESCP, Lama J, Cisneros I, Delgado JC, Slev P, Rychert J, Innis EA, Coiras M, Rondina MT, Spivak AM, Planelles V. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. Virol J 2021;18:1. [PMID: 33397387 DOI: 10.1186/s12985-020-01472-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 19.0] [Reference Citation Analysis]
174 Moi ML. [Dengue amidst COVID-19: challenges & control measures for the double burden]. Uirusu 2021;71:1-10. [PMID: 35526989 DOI: 10.2222/jsv.71.1] [Reference Citation Analysis]
175 Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med 2021;2:100189. [PMID: 33495758 DOI: 10.1016/j.xcrm.2020.100189] [Cited by in Crossref: 90] [Cited by in F6Publishing: 65] [Article Influence: 90.0] [Reference Citation Analysis]
176 Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, Rigby S, Williams SV, Bermingham WH, Kellam P, Maher J, Shields AM, Amirthalingam G, Peacock SJ, Ismail SA. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One 2020;15:e0244126. [PMID: 33382764 DOI: 10.1371/journal.pone.0244126] [Cited by in Crossref: 186] [Cited by in F6Publishing: 200] [Article Influence: 93.0] [Reference Citation Analysis]
177 Andryukov BG, Lyapun IN. COVID-19 diagnostic laboratory strategies: modern technologies and development trends (review of literature). Klin lab diagn 2020;65:757-66. [DOI: 10.18821/0869-2084-2020-65-12-757-766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Wang R, Jin F, Cao S, Yuan H, Qu J, Zhang J, Li Y, Chen X, Song W, Xie Z. Seroprevalence of SARS-CoV-2 infections among children visiting a hospital. Pediatr Investig 2020;4:236-41. [PMID: 33376950 DOI: 10.1002/ped4.12231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
179 Latiano A, Tavano F, Panza A, Palmieri O, Niro GA, Andriulli N, Latiano T, Corritore G, Gioffreda D, Gentile A, Fontana R, Guerra M, Biscaglia G, Bossa F, Carella M, Miscio G, di Mauro L. False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy. Int J Infect Dis 2021;104:159-63. [PMID: 33383223 DOI: 10.1016/j.ijid.2020.12.067] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
180 Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M, La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM, Parola P, Lagier JC, Brouqui P, Raoult D. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol 2020;16:1159-84. [PMID: 33356661 DOI: 10.1080/1744666X.2021.1847640] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 27.5] [Reference Citation Analysis]
181 Wang X, Yang C, Sun Y, Sui X, Zhu T, Wang Q, Wang S, Yang J, Yang W, Liu F, Zhang M, Wang Y, Luo Y. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. Environ Int 2021;147:106361. [PMID: 33401173 DOI: 10.1016/j.envint.2020.106361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
182 Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. bioRxiv 2020:2020. [PMID: 33398266 DOI: 10.1101/2020.12.20.414748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
183 Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front Immunol 2020;11:610688. [PMID: 33391281 DOI: 10.3389/fimmu.2020.610688] [Cited by in Crossref: 130] [Cited by in F6Publishing: 133] [Article Influence: 65.0] [Reference Citation Analysis]
184 Hassert M, Geerling E, Stone ET, Steffen TL, Feldman MS, Dickson AL, Class J, Richner JM, Brien JD, Pinto AK. mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. PLoS Pathog 2020;16:e1009163. [PMID: 33326500 DOI: 10.1371/journal.ppat.1009163] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
185 Hartanto H, Wu M, Lam ML, Chen TH. Microfluidic immunoassay for detection of serological antibodies: A potential tool for rapid evaluation of immunity against SARS-CoV-2. Biomicrofluidics 2020;14:061507. [PMID: 33343783 DOI: 10.1063/5.0031521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
186 Channappanavar R, Perlman S. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J Clin Invest 2020;130:6204-13. [PMID: 33085654 DOI: 10.1172/JCI144115] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
187 Kim DS, Rowland-Jones S, Gea-Mallorquí E. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Front Immunol 2020;11:571481. [PMID: 33362759 DOI: 10.3389/fimmu.2020.571481] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
188 Tan CC, Owen CJ, Tham CY, Bertoletti A, van Dorp L, Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses.. [DOI: 10.1101/2020.12.08.415703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
189 Bonam SR, Kotla NG, Bohara RA, Rochev Y, Webster TJ, Bayry J. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 2021;36:101051. [PMID: 33519949 DOI: 10.1016/j.nantod.2020.101051] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 20.5] [Reference Citation Analysis]
190 Wu NC, Yuan M, Bangaru S, Huang D, Zhu X, Lee CD, Turner HL, Peng L, Yang L, Burton DR, Nemazee D, Ward AB, Wilson IA. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog 2020;16:e1009089. [PMID: 33275640 DOI: 10.1371/journal.ppat.1009089] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
191 Pérez-López B, Mir M. Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages. Talanta 2021;225:121898. [PMID: 33592692 DOI: 10.1016/j.talanta.2020.121898] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
192 Vashishtha VM, Kumar P. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Hum Vaccin Immunother 2021;17:1635-49. [PMID: 33270478 DOI: 10.1080/21645515.2020.1845524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
193 Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child 2020:archdischild-2020-320338. [PMID: 33262177 DOI: 10.1136/archdischild-2020-320338] [Cited by in Crossref: 179] [Cited by in F6Publishing: 204] [Article Influence: 89.5] [Reference Citation Analysis]
194 Ahmad T, Chaudhuri R, Joshi MC, Almatroudi A, Rahmani AH, Ali SM. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Front Microbiol 2020;11:588409. [PMID: 33335518 DOI: 10.3389/fmicb.2020.588409] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
195 Taleghani N, Taghipour F. Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art. Biosens Bioelectron 2021;174:112830. [PMID: 33339696 DOI: 10.1016/j.bios.2020.112830] [Cited by in Crossref: 84] [Cited by in F6Publishing: 92] [Article Influence: 42.0] [Reference Citation Analysis]
196 Holenya P, Lange PJ, Reimer U, Woltersdorf W, Panterodt T, Glas M, Wasner M, Eckey M, Drosch M, Hollidt J, Naumann M, Kern F, Wenschuh H, Lange R, Schnatbaum K, Bier FF. Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.. [DOI: 10.1101/2020.11.24.20216663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
197 Taha BA, Al Mashhadany Y, Hafiz Mokhtar MH, Dzulkefly Bin Zan MS, Arsad N. An Analysis Review of Detection Coronavirus Disease 2019 (COVID-19) Based on Biosensor Application. Sensors (Basel) 2020;20:E6764. [PMID: 33256085 DOI: 10.3390/s20236764] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
198 Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, van Schooten J, Zhu X, Lee CD, Brouwer PJM, van Gils MJ, Sanders RW, Ward AB, Wilson IA. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity 2020;53:1272-1280.e5. [PMID: 33242394 DOI: 10.1016/j.immuni.2020.10.023] [Cited by in Crossref: 134] [Cited by in F6Publishing: 99] [Article Influence: 67.0] [Reference Citation Analysis]
199 Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G Jr, Arumugaswami V, Fries BC, Arditi M, Bahar I. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. bioRxiv 2020:2020. [PMID: 33269352 DOI: 10.1101/2020.11.24.395079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
200 Zeng C, Evans JP, Pearson R, Qu P, Zheng YM, Robinson RT, Hall-Stoodley L, Yount J, Pannu S, Mallampalli RK, Saif L, Oltz E, Lozanski G, Liu SL. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight 2020;5:143213. [PMID: 33035201 DOI: 10.1172/jci.insight.143213] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
201 Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, Diociaiuti A, El-Hachem M, Fertitta L, van Gysel D, Hernández-Martín A, Hubiche T, Luca C, Martos-Cabrera L, Maruani A, Mazzotta F, Akkaya AD, Casals M, Ferrando J, Grimalt R, Grozdev I, Kinsler V, Morren MA, Munisami M, Nanda A, Novoa MP, Ott H, Pasmans S, Salavastru C, Zawar V, Torrelo A; ESPD Group for the Skin Manifestations of COVID-19. Skin manifestations of COVID-19 in children: Part 3. Clin Exp Dermatol 2021;46:462-72. [PMID: 33207021 DOI: 10.1111/ced.14483] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
202 Kim H, Seiler P, Jones JC, Ridout G, Camp KP, Fabrizio TP, Jeevan T, Miller LA, Throm RE, Ferrara F, Fredrickson RL, Lowe JF, Wang L, Odemuyiwa SO, Wan XF, Webby RJ. Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals. Vaccines (Basel) 2020;8:E684. [PMID: 33207583 DOI: 10.3390/vaccines8040684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
203 Tharappel AM, Samrat SK, Li Z, Li H. Targeting Crucial Host Factors of SARS-CoV-2. ACS Infect Dis 2020;6:2844-65. [PMID: 33112126 DOI: 10.1021/acsinfecdis.0c00456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
204 Islam KU, Iqbal J. An Update on Molecular Diagnostics for COVID-19. Front Cell Infect Microbiol 2020;10:560616. [PMID: 33244462 DOI: 10.3389/fcimb.2020.560616] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 24.0] [Reference Citation Analysis]
205 Cimolai N. Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19. SN Compr Clin Med 2020;:1-14. [PMID: 33195997 DOI: 10.1007/s42399-020-00634-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
206 Zhu Y, Yu D, Han Y, Yan H, Chong H, Ren L, Wang J, Li T, He Y. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv 2020;6:eabc9999. [PMID: 33036961 DOI: 10.1126/sciadv.abc9999] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 20.5] [Reference Citation Analysis]
207 Rauf A, Abu-Izneid T, Olatunde A, Ahmed Khalil A, Alhumaydhi FA, Tufail T, Shariati MA, Rebezov M, Almarhoon ZM, Mabkhot YN, Alsayari A, Rengasamy KRR. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health 2020;17:E8155. [PMID: 33158234 DOI: 10.3390/ijerph17218155] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
208 Lon JR, Bai Y, Zhong B, Cai F, Du H. Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2. Virol J 2020;17:165. [PMID: 33121513 DOI: 10.1186/s12985-020-01437-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
209 Aran D, Beachler DC, Lanes S, Overhage JM. Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study. J Infect 2020;81:923-30. [PMID: 33127456 DOI: 10.1016/j.jinf.2020.10.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
210 Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, Beeman M, Mahmood T, Nze U, Gale BK. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. Anal Bioanal Chem 2021;413:49-71. [PMID: 33073312 DOI: 10.1007/s00216-020-02958-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 34.5] [Reference Citation Analysis]
211 Jing R, Kudinha T, Zhou ML, Xiao M, Wang H, Yang WH, Xu YC, Hsueh PR. Laboratory diagnosis of COVID-19 in China: A review of challenging cases and analysis. J Microbiol Immunol Infect 2021;54:17-26. [PMID: 33153907 DOI: 10.1016/j.jmii.2020.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
212 Lv H, So RTY, Yuan M, Liu H, Lee CD, Yip GK, Ng WW, Wilson IA, Peiris M, Wu NC, Mok CKP. Evidence of antigenic imprinting in sequential Sarbecovirus immunization.. [DOI: 10.1101/2020.10.14.339465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? Front Immunol 2020;11:567710. [PMID: 33178193 DOI: 10.3389/fimmu.2020.567710] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
214 Matthews MM, Kim TG, Shibata S, Shibata N, Butcher C, Hyun J, Kim KY, Robb T, Jheng SS, Narita M, Mori T, Collins M, Wolf M. COVID-19 serological survey using micro blood sampling.. [DOI: 10.1101/2020.10.09.20209858] [Reference Citation Analysis]
215 Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 2020;5:237. [PMID: 33051445 DOI: 10.1038/s41392-020-00352-y] [Cited by in Crossref: 303] [Cited by in F6Publishing: 320] [Article Influence: 151.5] [Reference Citation Analysis]
216 Ebrahimi N, Aslani S, Babaie F, Hemmatzadeh M, Hosseinzadeh R, Joneidi Z, Mehdizadeh Tourzani Z, Pakravan N, Mohammadi H. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. Int Immunopharmacol 2020;89:107082. [PMID: 33068865 DOI: 10.1016/j.intimp.2020.107082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
217 Yuan M, Liu H, Wu NC, Wilson IA. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun 2021;538:192-203. [PMID: 33069360 DOI: 10.1016/j.bbrc.2020.10.012] [Cited by in Crossref: 121] [Cited by in F6Publishing: 88] [Article Influence: 60.5] [Reference Citation Analysis]
218 Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Front Immunol 2020;11:576622. [PMID: 33117378 DOI: 10.3389/fimmu.2020.576622] [Cited by in Crossref: 179] [Cited by in F6Publishing: 198] [Article Influence: 89.5] [Reference Citation Analysis]
219 Ehaideb SN, Abdullah ML, Abuyassin B, Bouchama A. Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. Crit Care 2020;24:594. [PMID: 33023604 DOI: 10.1186/s13054-020-03304-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
220 Puccioni-Sohler M, Poton AR, Franklin M, Silva SJD, Brindeiro R, Tanuri A. Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19. Rev Soc Bras Med Trop 2020;53:e20200477. [PMID: 33027418 DOI: 10.1590/0037-8682-0477-2020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
221 Li T, Zheng Q, Yu H, Wu D, Xue W, Xiong H, Huang X, Nie M, Yue M, Rong R, Zhang S, Zhang Y, Wu Y, Wang S, Zha Z, Chen T, Deng T, Wang Y, Zhang T, Chen Y, Yuan Q, Zhao Q, Zhang J, Gu Y, Li S, Xia N. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerg Microbes Infect 2020;9:2076-90. [PMID: 32897177 DOI: 10.1080/22221751.2020.1821583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 20.5] [Reference Citation Analysis]
222 Zeng Q, Huang G, Li YZ, Xu Y. Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity. Mol Ther 2020;28:2314-5. [PMID: 33038327 DOI: 10.1016/j.ymthe.2020.09.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
223 Fedry J, Hurdiss DL, Wang C, Li W, Obal G, Drulyte I, Howes SC, van Kuppeveld FJ, Förster F, Bosch B. A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core.. [DOI: 10.1101/2020.09.30.318261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Ismail MB, Omari SA, Rafei R, Dabboussi F, Hamze M. COVID-19 in children: Could pertussis vaccine play the protective role? Med Hypotheses 2020;145:110305. [PMID: 33032174 DOI: 10.1016/j.mehy.2020.110305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
225 Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol 2021;99:21-33. [PMID: 32864735 DOI: 10.1111/imcb.12397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 21.5] [Reference Citation Analysis]
226 Lalaoui R, Bakour S, Raoult D, Verger P, Sokhna C, Devaux C, Pradines B, Rolain JM. What could explain the late emergence of COVID-19 in Africa? New Microbes New Infect 2020;38:100760. [PMID: 32983542 DOI: 10.1016/j.nmni.2020.100760] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
227 Wu K, Saha R, Su D, Krishna VD, Liu J, Cheeran MC, Wang J. Magnetic-Nanosensor-Based Virus and Pathogen Detection Strategies before and during COVID-19. ACS Appl Nano Mater 2020;3:9560-80. [DOI: 10.1021/acsanm.0c02048] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 21.5] [Reference Citation Analysis]
228 Wu NC, Yuan M, Bangaru S, Huang D, Zhu X, Lee CD, Turner HL, Peng L, Yang L, Nemazee D, Ward AB, Wilson IA. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. bioRxiv 2020:2020. [PMID: 32995788 DOI: 10.1101/2020.09.21.305441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
229 Cimolai N. A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. SN Compr Clin Med 2020;:1-8. [PMID: 32984765 DOI: 10.1007/s42399-020-00533-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
230 Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter W, Connor RI, Wright PF, Benner SE, Bonny TS, Laeyendecker O, Sullivan DJ, Shoham S, Quinn T, Larman HB, Casadevall A, Pekosz A, Redd A, Tobian AA, Ackerman ME. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. medRxiv 2020:2020. [PMID: 32995801 DOI: 10.1101/2020.09.16.20196154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
231 Wu SY, Yau HS, Yu MY, Tsang HF, Chan LWC, Cho WCS, Shing Yu AC, Yuen Yim AK, Li MJW, Wong YKE, Pei XM, Cesar Wong SC. The diagnostic methods in the COVID-19 pandemic, today and in the future. Expert Rev Mol Diagn 2020;20:985-93. [PMID: 32845192 DOI: 10.1080/14737159.2020.1816171] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
232 da Silva SJR, Silva CTAD, Guarines KM, Mendes RPG, Pardee K, Kohl A, Pena L. Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. ACS Infect Dis 2020;6:2319-36. [PMID: 32786280 DOI: 10.1021/acsinfecdis.0c00274] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
233 Fotis C, Meimetis N, Tsolakos N, Politou M, Akinosoglou K, Pliaka V, Minia A, Terpos E, Trougakos IP, Mentis A, Marangos M, Panayiotakopoulos G, Dimopoulos MA, Gogos C, Spyridonidis A, Alexopoulos LG. Robust SARS-COV-2 serological population screens via multi-antigen rules-based approach.. [DOI: 10.1101/2020.09.09.20191122] [Reference Citation Analysis]
234 Seyedpour S, Khodaei B, Loghman AH, Seyedpour N, Kisomi MF, Balibegloo M, Nezamabadi SS, Gholami B, Saghazadeh A, Rezaei N. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. J Cell Physiol 2021;236:2364-92. [PMID: 32901936 DOI: 10.1002/jcp.30032] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 23.0] [Reference Citation Analysis]
235 Diorio C, Anderson EM, McNerney KO, Goodwin EC, Chase JC, Bolton MJ, Arevalo CP, Weirick ME, Gouma S, Vella LA, Henrickson SE, Chiotos K, Fitzgerald JC, Kilbaugh TJ, John ARO, Blatz AM, Lambert MP, Sullivan KE, Tartaglione MR, Zambrano D, Martin M, Lee JH, Young P, Friedman D, Sesok-Pizzini DA, Hensley SE, Behrens EM, Bassiri H, Teachey DT. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer 2020;67:e28693. [PMID: 32885904 DOI: 10.1002/pbc.28693] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
236 Zhang P, Li B, Min W, Wang X, Li Z, Zhao Y, Zhang H, Jiang M, Zheng H, Yang C, Zhang W, Zuo L, Gao Q, Yang Z, Li Y, Feng T, Lin C, Hu Q, Song T, Yang R. Rapid evaluation of neutralizing antibodies in COVID-19 patients.. [DOI: 10.1101/2020.09.01.20185447] [Reference Citation Analysis]
237 Dearlove B, Lewitus E, Bai H, Li Y, Reeves DB, Joyce MG, Scott PT, Amare MF, Vasan S, Michael NL, Modjarrad K, Rolland M. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A 2020;117:23652-62. [PMID: 32868447 DOI: 10.1073/pnas.2008281117] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 78.5] [Reference Citation Analysis]
238 Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, Rigby S, Williams SV, Bermingham WH, Kellam P, Maher J, Shields AM, Amirthalingam G, Peacock SJ, Ismail SA. Antibody response to SARS-CoV-2 infection in humans: a systematic review.. [DOI: 10.1101/2020.08.25.20178806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
239 Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother 2020;16:3055-60. [PMID: 32845733 DOI: 10.1080/21645515.2020.1796425] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
240 Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, Raoult D, Merad M, Gachot B, Hénon C, Solary E, Fontenay M, André F, Maeurer M, Ippolito G, Piacentini M, Wang FS, Ginhoux F, Marabelle A, Kroemer G, Derosa L, Zitvogel L. Immune responses during COVID-19 infection. Oncoimmunology 2020;9:1807836. [PMID: 32939324 DOI: 10.1080/2162402X.2020.1807836] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 33.5] [Reference Citation Analysis]
241 Zellweger RM, Wartel TA, Marks F, Song M, Kim JH. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns. Expert Rev Vaccines 2020;19:691-8. [PMID: 32838605 DOI: 10.1080/14760584.2020.1800463] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
242 Samrat SK, Tharappel AM, Li Z, Li H. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Res 2020;288:198141. [PMID: 32846196 DOI: 10.1016/j.virusres.2020.198141] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 37.5] [Reference Citation Analysis]
243 Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J Gen Virol 2020;101:1156-69. [PMID: 32821033 DOI: 10.1099/jgv.0.001481] [Cited by in Crossref: 94] [Cited by in F6Publishing: 99] [Article Influence: 47.0] [Reference Citation Analysis]
244 Cheng Z, Zhang D, Liu X, Miao J, Wang J, Guo H, Yan W, Zhang Z, Zhang N, Wang J, Lu S, Zhang Z, Liu W, Liu H, Zhang Y, Zhang L, Dong J, Lemoine NR, Wang Y. An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2.. [DOI: 10.1101/2020.08.19.258244] [Reference Citation Analysis]
245 Cloutier M, Nandi M, Ihsan AU, Chamard HA, Ilangumaran S, Ramanathan S. ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine 2020;136:155256. [PMID: 32866898 DOI: 10.1016/j.cyto.2020.155256] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
246 Röltgen K, Wirz OF, Stevens BA, Powell AE, Hogan CA, Najeeb J, Hunter M, Sahoo MK, Huang C, Yamamoto F, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Nadeau KC, Jardetzky TS, Zehnder JL, Wang TT, Kim PS, Gombar S, Tibshirani R, Pinsky BA, Boyd SD. SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness. medRxiv 2020:2020. [PMID: 32839786 DOI: 10.1101/2020.08.15.20175794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
247 Moulahoum H, Ghorbanizamani F, Zihnioglu F, Turhan K, Timur S. How should diagnostic kits development adapt quickly in COVID 19-like pandemic models? Pros and cons of sensory platforms used in COVID-19 sensing. Talanta 2021;222:121534. [PMID: 33167242 DOI: 10.1016/j.talanta.2020.121534] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
248 Chauhan DS, Prasad R, Srivastava R, Jaggi M, Chauhan SC, Yallapu MM. Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. Bioconjug Chem 2020;31:2021-45. [PMID: 32680422 DOI: 10.1021/acs.bioconjchem.0c00323] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
249 Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20:633-643. [PMID: 32782358 DOI: 10.1038/s41577-020-00410-0] [Cited by in Crossref: 179] [Cited by in F6Publishing: 197] [Article Influence: 89.5] [Reference Citation Analysis]
250 Ma Z, Li P, Ikram A, Pan Q. Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses? Trends Immunol 2020;41:851-3. [PMID: 32863136 DOI: 10.1016/j.it.2020.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
251 Hassert M, Geerling E, Stone ET, Steffen TL, Dickson A, Feldman MS, Class J, Richner JM, Brien JD, Pinto AK. mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. bioRxiv 2020:2020. [PMID: 32793909 DOI: 10.1101/2020.08.07.241877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
252 Laskar P, Yallapu MM, Chauhan SC. "Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. Diseases 2020;8:E30. [PMID: 32781617 DOI: 10.3390/diseases8030030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
253 Scudellari M. How the pandemic might play out in 2021 and beyond. Nature 2020;584:22-5. [DOI: 10.1038/d41586-020-02278-5] [Cited by in Crossref: 147] [Cited by in F6Publishing: 154] [Article Influence: 73.5] [Reference Citation Analysis]
254 Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, van Schooten J, Zhu X, Lee CD, Brouwer PJM, van Gils MJ, Sanders RW, Ward AB, Wilson IA. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. bioRxiv 2020:2020. [PMID: 32793906 DOI: 10.1101/2020.08.02.233536] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
255 Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. Trends Pharmacol Sci 2020;41:815-29. [PMID: 32829936 DOI: 10.1016/j.tips.2020.07.004] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 43.0] [Reference Citation Analysis]
256 Bates TA, Weinstein JB, Farley SE, Leier HC, Messer WB, Tafesse FG. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. bioRxiv 2020:2020. [PMID: 32766589 DOI: 10.1101/2020.07.30.229377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
257 Bhalla N, Pan Y, Yang Z, Payam AF. Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. ACS Nano 2020;14:7783-807. [PMID: 32551559 DOI: 10.1021/acsnano.0c04421] [Cited by in Crossref: 196] [Cited by in F6Publishing: 208] [Article Influence: 98.0] [Reference Citation Analysis]
258 Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D'ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV. bioRxiv 2020:2020. [PMID: 32743570 DOI: 10.1101/2020.07.27.222943] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
259 Sood S, Aggarwal V, Aggarwal D, Upadhyay SK, Sak K, Tuli HS, Kumar M, Kumar J, Talwar S. COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. Curr Pharmacol Rep 2020;:1-16. [PMID: 32837855 DOI: 10.1007/s40495-020-00229-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
260 Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, Yeo NK, Torres-Ruesta A, Carissimo G, Poh CM, Chang ZW, Tay MZ, Chan YH, Chen MI, Low JG, Tambyah PA, Kalimuddin S, Pada S, Tan SY, Sun LJ, Leo YS, Lye DC, Renia L, Ng LFP. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine 2020;58:102911. [PMID: 32711254 DOI: 10.1016/j.ebiom.2020.102911] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 37.5] [Reference Citation Analysis]
261 Yu X. Risk Interactions of Coronavirus Infection across Age Groups after the Peak of COVID-19 Epidemic. Int J Environ Res Public Health 2020;17:E5246. [PMID: 32708118 DOI: 10.3390/ijerph17145246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
262 Kulkarni RB, Lederman Y, Afiari A, Savage JA, Jacob J. Morbilliform Rash: An Uncommon Herald of SARS-CoV-2. Cureus 2020;12:e9321. [PMID: 32850199 DOI: 10.7759/cureus.9321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
263 Pacheco-olvera DL, Remy-hernández SS, Acevedo-ochoa E, Arriaga-pizano L, Cérbulo-vázquez A, Ferat-osorio E, Rivera-hernández T, López-macías C. Bioinformatic analysis of shared B and T cell epitopes amongst relevant coronaviruses to human health: Is there cross-protection?. [DOI: 10.1101/2020.07.14.202887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
264 Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-daughton C, Lanzavecchia A, Corti D, Virgin HW. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 2020;584:353-63. [DOI: 10.1038/s41586-020-2538-8] [Cited by in Crossref: 334] [Cited by in F6Publishing: 339] [Article Influence: 167.0] [Reference Citation Analysis]
265 Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant FL, Gherardin NA, Pymm P, Dietrich MH, Scott NE, Tham WH, Godfrey DI, Subbarao K, Davenport MP, Kent SJ, Wheatley AK. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 2020;26:1428-34. [PMID: 32661393 DOI: 10.1038/s41591-020-0995-0] [Cited by in Crossref: 263] [Cited by in F6Publishing: 276] [Article Influence: 131.5] [Reference Citation Analysis]
266 Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, Mclawhon RW, Voss JE, Nemazee D, Fitzgerald RL. Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2.. [DOI: 10.1101/2020.07.10.20150946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
267 López-Collazo E, Avendaño-Ortiz J, Martín-Quirós A, Aguirre LA. Immune Response and COVID-19: A mirror image of Sepsis. Int J Biol Sci 2020;16:2479-89. [PMID: 32792851 DOI: 10.7150/ijbs.48400] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]
268 Altmann DM. Adaptive immunity to SARS-CoV-2. Oxf Open Immunol 2020;1:iqaa003. [PMID: 34192266 DOI: 10.1093/oxfimm/iqaa003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
269 Elizaldi SR, Lakshmanappa YS, Roh JW, Schmidt BA, Carroll TD, Weaver KD, Smith JC, Deere JD, Dutra J, Stone M, Sammak RL, Olstad KJ, Reader JR, Ma ZM, Nguyen NK, Watanabe J, Usachaenko J, Immareddy R, Yee JL, Weiskopf D, Sette A, Hartigan-O'Connor D, McSorley SJ, Morrison JH, Tran NK, Simmons G, Busch MP, Kozlowski PA, Van Rompay KKA, Miller CJ, Iyer SS. SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques. bioRxiv 2020:2020. [PMID: 32676606 DOI: 10.1101/2020.07.07.191007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
270 Cheah IK, Halliwell B. Could Ergothioneine Aid in the Treatment of Coronavirus Patients? Antioxidants (Basel) 2020;9:E595. [PMID: 32646061 DOI: 10.3390/antiox9070595] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
271 Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). Clin Chim Acta 2020;510:35-46. [PMID: 32621814 DOI: 10.1016/j.cca.2020.06.045] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 36.0] [Reference Citation Analysis]
272 Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020;5:eabc8413. [PMID: 32527802 DOI: 10.1126/sciimmunol.abc8413] [Cited by in Crossref: 560] [Cited by in F6Publishing: 568] [Article Influence: 280.0] [Reference Citation Analysis]
273 Rohn H, Feldkamp T, Witzke O. [COVID-19 and the kidneys]. Nephrologe 2020;:1-6. [PMID: 32837571 DOI: 10.1007/s11560-020-00444-4] [Reference Citation Analysis]
274 Lv H, Wu NC, Mok CKP. COVID-19 vaccines: Knowing the unknown. Eur J Immunol 2020;50:939-43. [PMID: 32437587 DOI: 10.1002/eji.202048663] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
275 Klimstra WB, Tilston-Lunel NL, Nambulli S, Boslett J, McMillen CM, Gilliland T, Dunn MD, Sun C, Wheeler SE, Wells A, Hartman AL, McElroy AK, Reed DS, Rennick LJ, Duprex WP. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients. bioRxiv 2020:2020. [PMID: 32607507 DOI: 10.1101/2020.06.19.154930] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
276 Faustini SE, Jossi SE, Perez-Toledo M, Shields A, Allen JD, Watanabe Y, Newby ML, Cook A, Willcox CR, Salim M, Goodall M, Heaney JL, Marcial-Juarez E, Morley GL, Torlinska B, Wraith DC, Veenith T, Harding S, Jolles S, Mark PJ, Plant T, Huissoon A, O'Shea MK, Willcox BE, Drayson MT, Crispin M, Cunningham AF, Richter AG. Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. medRxiv 2020:2020. [PMID: 32588002 DOI: 10.1101/2020.06.16.20133025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 23.0] [Reference Citation Analysis]
277 Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020;94:e00510-20. [PMID: 32303592 DOI: 10.1128/jvi.00510-20] [Cited by in Crossref: 302] [Cited by in F6Publishing: 337] [Article Influence: 151.0] [Reference Citation Analysis]
278 Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, Jangra RK, Dieterle ME, Lilov A, Huang D, Tse LV, Johnson NV, Hsieh CL, Wang N, Nett JH, Champney E, Burnina I, Brown M, Lin S, Sinclair M, Johnson C, Pudi S, Bortz R 3rd, Wirchnianski AS, Laudermilch E, Florez C, Fels JM, O'Brien CM, Graham BS, Nemazee D, Burton DR, Baric RS, Voss JE, Chandran K, Dye JM, McLellan JS, Walker LM. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020;369:731-6. [PMID: 32540900 DOI: 10.1126/science.abc7424] [Cited by in Crossref: 434] [Cited by in F6Publishing: 426] [Article Influence: 217.0] [Reference Citation Analysis]
279 Gurzawska-Comis K, Becker K, Brunello G, Gurzawska A, Schwarz F. Recommendations for Dental Care during COVID-19 Pandemic. J Clin Med 2020;9:E1833. [PMID: 32545477 DOI: 10.3390/jcm9061833] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 19.5] [Reference Citation Analysis]
280 Fierz W, Walz B. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS. Front Immunol 2020;11:1120. [PMID: 32582200 DOI: 10.3389/fimmu.2020.01120] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
281 Tong PB, Lin LY, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies help? Life Sci 2020;255:117836. [PMID: 32450171 DOI: 10.1016/j.lfs.2020.117836] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
282 Yu X. Risk interactions of coronavirus infection across age groups after the peak of COVID-19 epidemic.. [DOI: 10.1101/2020.05.17.20105049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
283 Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R, Xie XS. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell 2020;182:73-84.e16. [PMID: 32425270 DOI: 10.1016/j.cell.2020.05.025] [Cited by in Crossref: 902] [Cited by in F6Publishing: 908] [Article Influence: 451.0] [Reference Citation Analysis]
284 Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 2020;12:E513. [PMID: 32384820 DOI: 10.3390/v12050513] [Cited by in Crossref: 431] [Cited by in F6Publishing: 457] [Article Influence: 215.5] [Reference Citation Analysis]
285 Mboowa G. Current and emerging diagnostic tests available for the novel COVID-19 global pandemic. AAS Open Res 2020;3:8. [PMID: 32537561 DOI: 10.12688/aasopenres.13059.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
286 [DOI: 10.1101/2020.07.15.20147041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
287 [DOI: 10.1101/2021.01.31.428824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
288 [DOI: 10.1101/2020.09.21.20196428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
289 [DOI: 10.1101/2020.08.13.249953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
290 [DOI: 10.1101/2020.10.14.20212662] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Reference Citation Analysis]